

Annex 8 - Clinical information on the included participants										
Participant	BRMI			CEM				Diagnose and treatment		Conclusion
	Mass	NME	Total extent of disease (size in mm.)	Mass	NME	M-C	Total extent of disease (size in mm.)	Histopathology	Treatment	
20501	2	2	108	2	2	-	100	IDC NST s. 3&4	Mastectomy	True positive
20502	-	2	120	-	2	-	125	IDC NST s. 3 + DSIS s. 3	Neoadjuvant + ablatio	True positive
20503	2	-	26	2	2	2	34	IDC NST s. 3 + DCIS s. 3	BCT/SN	True positive
20504	-	-	-	-	-	-	-	Negative	-	True negative
20505	-	1	11	-	1	-	47	Negative	-	True negative
20506	-	-	-	-	-	-	-	Negative	-	True negative
20507A	2	2	50	2	-	-	9	ITC s. 1 + ITC/ILC s. 1	BCT/SN	True positive
20507B	1	-	12	2	-	-	9	FA	None	TN on BRMI/ FP on CEM
20508	2	-	40	2	-	-	42	IDC NST s. 20	Neoadjuvant + ablatio	True positive
20509	-	2	50	2	-	-	44	IDC NST s. 3	Neoadjuvant + BCT/SN	True positive
20510	2	-	50	2	-	-	49	ILC s. s. 1&2 + LCIS	Neoadjuvant + sub. mastectomy	True positive
20511	2	2	70	2	2	2	63	IDC NST s. 2 + DCIS s.1	Neoadjuvant + sub. mastectomy	True positive
20512	2	-	24	2	-	-	22	IDC NST s. 3 + DCIS s. 3	Ablatio	True positive
20513	2	-	60	2	-	2	75	IDC NST g. 1&2 + DCIS s. 1&2	Sub. mastectomy	True positive
20514	-	2	75	2	-	-	81	ILC s. 3	Neoadjuvant + BCT/SN	True positive
20515	2	2	100	2	2	-	92	IDC NST s. 2 + DCIS s. 3	Neoadjuvant + BCT/SN	True positive
20516	2	-	19	2	-	-	17	IDC NST s. 3	BCT/SN	True positive
20517	2	2	56	2	2	-	52	ILC s. 3	BCT/SN	True positive
20518	2	-	43	2	-	2	56	IDC NST s. 2 + DCIS s. 1	BCT/SN	True positive
20519	-	-	-	-	-	2	90	DCIS s. 1&2	BCT	FN on BRMI/ TP on CEM
20520A	2	-	10	2	-	-	8	IDC NST s. 1 + DCIS s. 1	BCT/SN	True positive
20520B	2	-	5	2	-	-	5	IDH	None	False positive on both
20521	2	-	80	2	2	-	115	ILC s. 2	Neoadjuvant + sub. mastectomy	True positive
20522	2	-	45	2	-	-	19	ILC s. 2 + ITC s. 1 + DCIS s. 1&3	BCT/SN	True positive
20523	2	-	22	1	-	-	10	IMC s. 2 + DCIS s. 3	BCT/SN	TP on BRMI/ FN on CEM
20524	2	-	45	2	-	-	25	IDC NST s. 2 + DCIS s. 1	BCT/SN	True positive
20525	2	2	80	2	-	-	55	IDC NST s. 3	Neoadjuvant + ablatio	True positive
20528	-	2	70	-	-	-	-	DCIS s. 1	Ablatio	TP on BRMI/ FN on CEM
20529	2	-	35	2	-	-	35	IDC NST s. 1 + DCIS s. 1	Ablatio	True positive
20530	2	2	50	2	2	2	53	IDC NST s. 3 + DCIS s. 3	Ablatio + SN	True positive
20531	2	2	45	2	2	-	40	ILC s. 2	Neoadjuvant + BCT/SN	True positive
20533	2	-	45	2	-	-	55	IDC NST s. 2 + DCIS s. 1	BCT/SN	True positive

Note: Mass, NME, and M-C definitions: 1 = negative, benign, or likely benign, 2 = uncertain, likely malignant, or malignant. For participants 20507 and 20520: A = index finding, B = additional finding in contralateral breast.

Abbreviations: NME = non-mass enhancement, M-C = micro-calcification, IDC = invasive ductal carcinoma, ITC = invasive tubular carcinoma, ILC = invasive lobular carcinoma, IDH = intraductal hyperplasia, IMC = invasive mucinous carcinoma, NST = no special type, TN = triple negative, DCIS = ductal carcinoma in situ, LCIS = lobular carcinoma in situ, BCT = breast-conserving therapy, SN = sentinel node, FA = fibroadenoma, sub. = subcutaneous, s. = stage